CompletedPhase 4ACTRN12613000902796

Palonosetron and aprepitant for prevention of postoperative nausea and vomiting in patient undergoing laparoscopic gynecology surgery.

In patients undergoing laparoscopic gynecologic surgery, which is more effective for the prevention of postoperative nausea and vomiting between palonosetron and aprepitant.


Sponsor

Chung-ang university

Enrollment

100 participants

Start Date

Oct 1, 2011

Study Type

Interventional

Conditions

Summary

Postoperative nausea and vomiting (PONV) frequently develops in patients undergoing laparoscopic gynecologic surgery, The present study was undertaken to compare the effects of palanosetron and aprepitant on PONV in patients following laparoscopic gynecologic surgery. Patients were randomly assigned to one of two groups to receive antiemetics as follows: palanosetron 0.075 mg or aprepitant 40 mg. PONV, postoperative pain intensity, rescue antiemetics requirement, and side effects were assessed at 0, 2, 6, 24, 48 hr postoperatively.


Eligibility

Sex: FemalesMin Age: 20 YearssMax Age: 60 Yearss

Inclusion Criteria1

  • patients undergoing laparoscopic gynecologic surgery

Exclusion Criteria1

  • Pregnant women, 60 years of age or older and under 20 years old, weight 45kg or less, or more than 100kg, more than American society of Anesthesiologist grade three , history of previous postoperative nausea and vomiting, history of motion sickness, smokers, patient of serious cardiovascular system, kidney, liver, and hematological abnormalities.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

before 1 hour to induction of anesthesia aprepitant 40 mg was given to patients by oral

before 1 hour to induction of anesthesia aprepitant 40 mg was given to patients by oral


Locations(1)

Korea, Republic Of

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12613000902796